Procedure and treatment
In the study group, PEG-rhG-CSF was given subcutaneously at a dose of 6 mg for patients weighing ≥45 kg or 3 mg for those weighing <45 kg after 48 h of completing one chemotherapy cycle. In the control arm, rhG-CSF was injected subcutaneously at 48 h after the end of chemotherapy at a dose of 300 µg for those weighing ≥45 kg or 150 µg for those weighing <45 kg once a day for three consecutive days. In both groups, if the white blood cell count (WBC) was less than 2 × 10All patients underwent three-dimensional conformal or intensity-modulated radiotherapy of the clinical target at 50 Gy in 25 daily fractions and two cycles of concurrent chemotherapy, followed by an intracavitary brachytherapy boost using a high dose rate technique and two cycles of adjuvant chemotherapy. The metastatic lymph nodes were treated with a simultaneous integrated boost regimen of 62.5 Gy in 25 fractions. Chemotherapy was given once every 21 days and comprised a dual-agent regimen of intravenous docetaxel at 60–75 mg/mBasic characteristics of the patientsPEG-rhG-CSF: Pegylated recombinant human granulocyte colony-stimulating factor; rhG-CSF: Recombinant human granulocyte colony-stimulating factor; FIGO: International Federation of Gynecology and Obstetrics.